A new “smart pill” bottle which prompts patients to take their medications on time and notifies doctors when it has been dispensed, has shown 100% reliability in improving medication adherence.
“Drugs don’t work in patients that don’t take them”
There are an estimated 200,000 avoidable deaths in the European Union (EU) due to non-adherence, as well as €125 billion in unnecessary costs to the healthcare system. Poor adherence hinders disease control and leads to a lower quality of life for patients. For medication regimens to be effective, correct adherence is essential. Unfortunately, poor patient adherence is a large problem, not only in everyday clinical healthcare, but in clinical trials as well.
For sponsors conducting clinical trials in the industry, it is difficult to accurately determine true adherence levels, which can affect the quality of data to be analysed. Poor quality data can lead to an inaccurate outcome of a trial, possibly affecting the overall efficacy of the treatment, thereby influencing the data submitted to regulatory authorities. Hence, it is essential that non-adherence is challenged in clinical trials.
The “smart pill” bottle is connected to an app, which is pre-installed with the dosing regimen intended by the prescriber. The app sends a reminder to the patient to take a pill at a pre-determined time, then the patient responds to the reminder, a pill is dispensed and the data is sent to a control centre. Additionally, the pill is actually locked outside of dosage times to prevent double dosing. The patient will be fully trained on how to use the app by an appropriate healthcare professional.
This new technology is a possible solution to the burden of non-adherence affecting trial outcomes in the pharmaceutical industry, potentially improving the clinical efficacy and safety of medicinal products in the long-term. For more information, click here.